Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

ClinicalTrials.gov ID: NCT00082589

Public ClinicalTrials.gov record NCT00082589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure

Study identification

NCT ID
NCT00082589
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
250 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2004 (Type not available)
Primary completion
Not listed
Completion
Mar 2006 (Type not available)
Last update posted
Dec 22, 2020

2004 – 2006

United States locations

U.S. sites
53
U.S. states
25
U.S. cities
45
Facility City State ZIP Site status
Pfizer Investigational Site Castro Valley California 94546 —
Pfizer Investigational Site San Diego California 92103-8411 —
Pfizer Investigational Site Santa Rosa California 95403 —
Pfizer Investigational Site Walnut Creek California 94598-3084 —
Pfizer Investigational Site Denver Colorado 80262 —
Pfizer Investigational Site New Haven Connecticut 06510 —
Pfizer Investigational Site Fort Lauderdale Florida 33308 —
Pfizer Investigational Site Jacksonville Florida 32209 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Atlanta Georgia 30309-1721 —
Pfizer Investigational Site Augusta Georgia 30901 —
Pfizer Investigational Site Covington Georgia 30014 —
Pfizer Investigational Site Boise Idaho 83704-0107 —
Pfizer Investigational Site Bloomington Illinois 61701 —
Pfizer Investigational Site Normal Illinois 61761 —
Pfizer Investigational Site Indianapolis Indiana 46202 —
Pfizer Investigational Site Indianapolis Indiana 46260 —
Pfizer Investigational Site Auburn Maine 04210 —
Pfizer Investigational Site Ann Arbor Michigan 48105 —
Pfizer Investigational Site Detroit Michigan 48201 —
Pfizer Investigational Site Minneapolis Minnesota 55415 —
Pfizer Investigational Site Minneapolis Minnesota 55422 —
Pfizer Investigational Site St Louis Missouri 63104 —
Pfizer Investigational Site St Louis Missouri 63110-0250 —
Pfizer Investigational Site St Louis Missouri 63110 —
Pfizer Investigational Site St Louis Missouri 63117 —
Pfizer Investigational Site Lexington Nebraska 68850 —
Pfizer Investigational Site Lincoln Nebraska 68516 —
Pfizer Investigational Site McCook Nebraska 69001 —
Pfizer Investigational Site Lebanon New Hampshire 03756 —
Pfizer Investigational Site Albany New York 12205 —
Pfizer Investigational Site Manhasset New York 11030 —
Pfizer Investigational Site New York New York 10032 —
Pfizer Investigational Site West Islip New York 11795 —
Pfizer Investigational Site Mount Airy North Carolina 27030 —
Pfizer Investigational Site Winston-Salem North Carolina 27109 —
Pfizer Investigational Site Cincinnati Ohio 45219 —
Pfizer Investigational Site Lorain Ohio 44053 —
Pfizer Investigational Site Sandusky Ohio 44870-3390 —
Pfizer Investigational Site Oklahoma City Oklahoma 73120 —
Pfizer Investigational Site Philadelphia Pennsylvania 19104 —
Pfizer Investigational Site Philadelphia Pennsylvania 19107 —
Pfizer Investigational Site Sayre Pennsylvania 18840 —
Pfizer Investigational Site Pawtucket Rhode Island 02860 —
Pfizer Investigational Site Charleston South Carolina 29401 —
Pfizer Investigational Site Germantown Tennessee 38138 —
Pfizer Investigational Site Nashville Tennessee 37212 —
Pfizer Investigational Site Beaumont Texas 77630 —
Pfizer Investigational Site Beaumont Texas 77702 —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site Galax Virginia 24333 —
Pfizer Investigational Site Roanoke Virginia 24014 —
Pfizer Investigational Site Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00082589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2020 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00082589 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →